Memantine Centrafarm

Memantine, the active ingredient in Memantine Centrafarm, is a NMDA receptor antagonist presented as a tablet for oral use. It treats Alzheimer’s disease in adults with mild to moderate dementia.

GNH USA supplies Memantine Centrafarm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is an NMDA receptor antagonist used in the management of neurodegenerative conditions.

Alzheimer's disease (mild to moderate): improves cognition and daily functioning. Alzheimer's disease (moderate to severe): helps maintain functional abilities. Alzheimer's disease (behavioral symptoms): may reduce agitation and improve overall patient behavior.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue - Confusion - Hypertension

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmias - Stevens‑Johnson syndrome or severe skin reactions - Hepatic injury - Suicidal thoughts or behavior

Memantine should be used with caution in several clinical situations.

Renal impairment: adjust dose or monitor renal function. Hepatic impairment: use with caution; monitor liver enzymes. History of seizures: monitor closely for increased seizure activity. Concurrent NMDA antagonists: avoid additive neuro‑psychiatric effects. Pregnancy: safety unknown; avoid unless clearly needed. Store at ambient temperature: keep in original container, protect from moisture.

Memantine may interact with several medicines.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neuro‑psychiatric effects. - Ketamine: combined CNS depression risk. - Other NMDA antagonists: heightened risk of adverse neurologic events.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance hypotensive effect. - Diuretics: increased risk of dehydration and electrolyte imbalance. - Anticholinergics: may worsen cognitive impairment.